A recent phase 1 clinical trial of the PRMT5 inhibitor JNJ-64619178 in patients with lower-risk MDS demonstrated target engagement and tolerability, although its clinical efficacy was found to be limited [58]. This evidence concerns the gene PRMT5 and myelodysplastic syndrome.